🏛️ Verified NIH Record • Updated 2026-05-03
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors (NCT06239194)
A Phase 1/2a, Multicenter, First-in-human, Open-label Clinical Trial Evaluating MDX2001 Monotherapy in Patients With Advanced Solid Tumors
🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: ModeX Therapeutics, An OPKO Health Company
🩺 Plain-English Summary (8th-Grade Level)
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Who can join: Review the eligibility criteria below.
Location: Sarah Cannon Research Institute — Denver, Colorado
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (6 Sites)
- Sarah Cannon Research Institute — Denver, Colorado
- Sylvester Comprehensive Cancer Center - University of Miami Health System — Miami, Florida
- Massachusetts General Hospital — Boston, Massachusetts
- Sarah Cannon Research Institute — Nashville, Tennessee
- MD Anderson Cancer Center — Houston, Texas
- NEXT Oncology — San Antonio, Texas
📞 Contact the Study Coordinator
Phone: (857) 233-9936
Email: info@modextx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Biliary Tract Cancer
- Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers — Pittsburgh, Pennsylvania
- Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) — Birmingham, Alabama
- A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer — Tucson, Arizona
- Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) — Mobile, Alabama
- XmAb20717 in Advanced Biliary Tract Cancers — Philadelphia, Pennsylvania
- A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) — Phoenix, Arizona
Explore by condition: All Biliary Tract Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.